Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a...
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers.
Target Price
The average target price of ARMP is 9.0 and suggests 57% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell